WiseGuyReports.com adds “Gastroparesis – Market Insights, Epidemiology and Market Forecast-2027” reports to its database.
A digestive disorder in which the motility of the stomach is impaired which leads to the stomach being unable to empty itself in a normal fashion is called gastroparesis or stomach paralysis. People affected by this condition can’t properly crush the food and push it into the small intestine which leads to indigestion. When solid food, foods that are high in fiber like raw vegetables and fruits, drinks or food that have a high fat content are ingested, the symptoms of gastroparesis may manifest.
There are various problems that are caused by gastroparesis which include fermentation of food that has stayed in the stomach for too long which leads to the growth of bacteria. Bezoars can also cause blockages which prevent food from passing to the small intestines. Bezoar is food that has hardened into a solid mass in the stomach. Dehydration and malnutrition are common symptoms when one is affected by gastroparesis. Blood glucose levels can increase drastically when food finally enters the small intestine.
The report published on gastroparesis market includes the current treatment practices that are used to treat diseases as well as various unmet needs in the current industry. The market share of individual therapies used as well as the current and forecasted size of gastroparesis market is included in the report. The current treatment algorithms, emerging drugs, market barriers, market drivers and unmet needs are comprehensively covered and the best opportunities are curated to accurately gauge the underlying market potential. Treatment algorithms as well as the treatment guidelines are included in the report.
The report ‘Gastroparesis – Market Insights, Epidemiology and Market Forecast-2027’ differentiates it into two main market segments namely epidemiology and the various drug chapters. On the basis of epidemiology it can be characterized into four main types which include gender specific prevalence, prevalent cases, diagnosed and treatable population and severity based prevalence. The different drugs are categorized mainly into prokinetic or promotility agents (Metoclopramide, Domperidone, Erythromycin, and Cisapride), antiemetic agents and a nerve blocking agent called botulinum toxin injection. The only drug which has been approved to treat gastroparesis by the United States Food and Drug Administration is metoclopramide with the others being up to the physician to recommend them or not.
The report ‘Gastroparesis – Market Insights, Epidemiology and Market Forecast-2027’ provides an in depth understanding of gastroparesis disease and analyzes the forecasted as well as historical epidemiology in various regions around the world which include the United States, Italy, France, Spain, Germany, the United Kingdom and Japan. For the various regions covered in the report from the year 2016 to the year 2027 the total number of cases in each region, the gender based prevalence of the disease, the severity based prevalence of gastroparesis and well as the diagnosed cases and the treatable number of cases in analyzed in detail in the report.
The pharmaceutical company Evoke Pharma. Inc which focuses on treatments for gastrointestinal diseases recently completed the manufacture of commercial batches of its product, Gimoti. Gimoti which is a metoclopramide nasal spray is manufactured along with its partner Thermo Fisher Scientific which is an organization that specializes in nasal spray products.
For further information on this report, visit – https://www.wiseguyreports.com/reports/3320976-gastroparesis-market-insights-epidemiology-and-market-forecast-2027
Ph: +1-646-845-9349 (US); +44 208 133 9349 (UK)